Drug Information
Drug (ID: DG00027) and It's Reported Resistant Information
| Name |
Tretinoin
|
||||
|---|---|---|---|---|---|
| Synonyms |
Retinoic acid; tretinoin; 302-79-4; Vitamin A acid; all-trans-Retinoic acid; trans-Retinoic acid; ATRA; Airol; Retin-A; Vesanoid; Renova; Dermairol; Aknoten; Eudyna; Aberel; all-trans-Vitamin A acid; Aknefug; All-trans Retinoic Acid; Cordes vas; Epi-aberel; Atralin; Vitamin A1 acid, all-trans-; Tretin M; Retin-A Micro; all-trans-Vitamin A1 acid; Vitamin A acid, all-trans-; all-trans-Tretinoin; Effederm; Retionic acid; TRETINON; Retinoic acid, all-trans-; Alltrans-retinoic acid; beta-Ra; all-(E)-Retinoic acid; beta-Retinoic acid; Avitoin; Aberela; Acnavit; Atragen; Betarretin; Lsotretinoin; Nexret; Panretyn; REA; Retacnyl; Retinoate; Retinova; Solage; Tretinoina; Tretinoine; Tretinoino; Tretinoinum; Vesnaroid; Vitinoin; Aberela [Norway]; Accutane Roche; Acnavit [Denmark]; All Trans Retinoic Acid; Avita Gel; Avitoin [Norway]; Beta all trans Retinoic Acid; Cordes VAS [Germany]; Effederm [France]; Panretin Gel; Retin A; Trans Retinoic Acid; Tretinoin Potassium Salt; Tretinoin Sodium Salt; Tretinoin Zinc Salt; Tretinoin liposome; AGN100335; AGN 192013; ALRT 1057; BAL4079; LGD 100057; R 2625; [3H]Retinoic acid; A-Vitaminsyre; A-Vitaminsyre [Denmark]; AT-RA; Aberela (TN); Acid, Retinoic; Acid, Vitamin A; All trans-Retinoic acid; Atra-IV; Avita (TN); B-Retinoic acid; BML2-E05; Beta-Ra; Beta-Retinoic acid; Potassium Salt, Tretinoin; RETINOIC ACID, ALL TRANS; Renova (TN); Retin A (TN); Retisol-A; Ro 1-5488; Salt, Tretinoin Potassium; Salt, Tretinoin Sodium; Salt, Tretinoin Zinc; Sodium Salt, Tretinoin; Stieva-A; Stieva-a Forte; Trans-Retinoicacid; Tretinoin (TN); Tretinoina [INN-Spanish]; Tretinoine [INN-French]; Tretinoino [INN-Spanish]; Tretinoinum [INN-Latin]; Tri-Luma; Vesanoid (TN); Zinc Salt, Tretinoin; A-Acido (Argentina); Acid A Vit (Belgium, Netherlands); Acid, trans-Retinoic; Acide retinoique (French) (DSL); All-trans-Retinoic acid; All-trans-Tretinoin; All-trans-Vitamin A acid; All-trans-Vitamin A1 acid; PDT-002-002; Retin-A (TN); Stieva-A (TN); Tretinoin 01% cream or placebo; Tretinoin [USAN:INN:BAN]; Tretinoin/All-Trans Retinoic Acid; Tretinoine (French) (EINECS); Acid, all-trans-Retinoic; All-(E)-Retinoic acid; All-trans-b-Retinoic acid; All-trans-beta-Retinoic acid; Beta-all-trans-Retinoic acid; Tretinoin (JAN/USP/INN); Acid, beta-all-trans-Retinoic; Retinoic acid, all-trans-(8CI); Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin; 15-Apo-beta-caroten-15-oic acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; 9(Z)-Retinoic acid; 9-cis-RA; 9-trans-retinoic acid
Click to Show/Hide
|
||||
| Indication |
In total 2 Indication(s)
|
||||
| Structure |
|
||||
| Drug Resistance Disease(s) |
Disease(s) with Clinically Reported Resistance for This Drug
(2 diseases)
Acute myeloid leukemia [ICD-11: 2A60]
[3]
|
||||
| Target | Retinoic acid receptor (RAR) | NOUNIPROTAC | [1] | ||
| Retinoic acid receptor gamma (RARG) | RARG_HUMAN | [1] | |||
| Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
| Formula |
C20H28O2
|
||||
| IsoSMILES |
CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C
|
||||
| InChI |
1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+
|
||||
| InChIKey |
SHGAZHPCJJPHSC-YCNIQYBTSA-N
|
||||
| PubChem CID | |||||
| ChEBI ID | |||||
| TTD Drug ID | |||||
| VARIDT ID | |||||
| INTEDE ID | |||||
| DrugBank ID | |||||
Type(s) of Resistant Mechanism of This Drug
ADTT: Aberration of the Drug's Therapeutic Target
UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Brain cancer [ICD-11: 2A00]
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
Unusual Activation of Pro-survival Pathway (UAPP)
|
||||
| Key Molecule: Neurofibromin (NF1) | [1], [2] | |||
| Molecule Alteration | Alteration | . |
||
| Resistant Disease | Neuroblastoma [ICD-11: 2A00.11] | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| Cell Pathway Regulation | MAPK/RAS signaling pathway | Activation | hsa04010 | |
| In Vitro Model | Kelly cells | Adrenal | Homo sapiens (Human) | CVCL_2092 |
| Sk-N-AS cells | Adrenal | Homo sapiens (Human) | CVCL_1700 | |
| IMR-5 cells | Brain | Homo sapiens (Human) | CVCL_1306 | |
| NBL-S cells | Brain | Homo sapiens (Human) | CVCL_2136 | |
| Experiment for Molecule Alteration |
Whole genome sequencing assay | |||
| Experiment for Drug Resistance |
MTT assay | |||
| Mechanism Description | NF1 i.ctivation has been reported in neuroblastoma and confers activation of RAS-MAPk signalling and resistance to retinoic acid. | |||
Acute myeloid leukemia [ICD-11: 2A60]
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
Aberration of the Drug's Therapeutic Target (ADTT)
|
||||
| Key Molecule: ZBTB16-RARA fusion protein (ZBTB16-RARA) | [3] | |||
| Molecule Alteration | Structural mutation | Structural variation |
||
| Resistant Disease | Acute myeloid leukemia [ICD-11: 2A60.0] | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| Cell Pathway Regulation | AKT/PI3 signaling pathway | Activation | hsa04151 | |
| MAPK signaling pathway | Activation | hsa04010 | ||
| STAT signaling pathway | Activation | hsa04630 | ||
| Experiment for Molecule Alteration |
Next-generation sequencing assay | |||
| Mechanism Description | However, rarer variant translocations such as t(11;17)(q23;q21); ZBTB16-RARA or t(17;17)(q21;q21); STAT5B-RARA may result in resistance to ATRA. | |||
| Key Molecule: STAT5B-RARA fusion protein (STAT5B-RARA) | [3] | |||
| Molecule Alteration | Structural mutation | Structural variation |
||
| Resistant Disease | Acute myeloid leukemia [ICD-11: 2A60.0] | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| Cell Pathway Regulation | AKT/PI3 signaling pathway | Activation | hsa04151 | |
| MAPK signaling pathway | Activation | hsa04010 | ||
| STAT signaling pathway | Activation | hsa04630 | ||
| Experiment for Molecule Alteration |
Next-generation sequencing assay | |||
| Mechanism Description | However, rarer variant translocations such as t(11;17)(q23;q21); ZBTB16-RARA or t(17;17)(q21;q21); STAT5B-RARA may result in resistance to ATRA. | |||
|
Unusual Activation of Pro-survival Pathway (UAPP)
|
||||
| Key Molecule: t(17;17)(q21;q21) (Unclear) | [3] | |||
| Molecule Alteration | Structural mutation | Structural variation |
||
| Resistant Disease | Acute myeloid leukemia [ICD-11: 2A60.0] | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| Cell Pathway Regulation | AKT/PI3 signaling pathway | Activation | hsa04151 | |
| MAPK signaling pathway | Activation | hsa04010 | ||
| STAT signaling pathway | Activation | hsa04630 | ||
| Experiment for Molecule Alteration |
Next-generation sequencing assay | |||
| Mechanism Description | However, rarer variant translocations such as t(11;17)(q23;q21); ZBTB16-RARA or t(17;17)(q21;q21); STAT5B-RARA may result in resistance to ATRA. | |||
| Key Molecule: t(11;17)(q23;q21) (Unclear) | [3] | |||
| Molecule Alteration | Structural mutation | Structural variation |
||
| Resistant Disease | Acute myeloid leukemia [ICD-11: 2A60.0] | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| Cell Pathway Regulation | AKT/PI3 signaling pathway | Activation | hsa04151 | |
| MAPK signaling pathway | Activation | hsa04010 | ||
| STAT signaling pathway | Activation | hsa04630 | ||
| Experiment for Molecule Alteration |
Next-generation sequencing assay | |||
| Mechanism Description | However, rarer variant translocations such as t(11;17)(q23;q21); ZBTB16-RARA or t(17;17)(q21;q21); STAT5B-RARA may result in resistance to ATRA. | |||
References
visits since 2022
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.